FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 658 shares for the 1-month period ending 2021-12-31, per its 10-K filed 2022-02-28.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2022-02-28
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-06-30 was 95.00K shares.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2018-03-31 was 210.00K shares.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-09-30 was 21.00K shares, a 92.63% decline year-over-year.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 1 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|---|---|
| 2021-12-31 | 658.00 shares 10-K · filed 2022-02-28 | ||||
| 2018-06-30 | 95.00K shares 10-Q · filed 2018-08-13 | 305.00K shares derived: sum of 2 quarters · filed 2018-08-13 | |||
| 2018-03-31 | 210.00K shares 10-Q · filed 2018-05-14 | ||||
| 2017-09-30 | 21.00K shares 10-Q · filed 2017-11-13 | 21.00K shares derived: sum of 2 quarters · filed 2018-08-13 | 21.00K shares derived: sum of 3 quarters · filed 2018-08-13 | ||
| 2017-06-30 | 0.00 shares 10-Q · filed 2018-08-13 | 300.00K shares 10-Q · filed 2017-08-14 | 0.00 shares derived: sum of 2 quarters · filed 2018-08-13 | ||
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-14 | ||||
| 2016-09-30 | 285.00K shares 10-Q · filed 2017-11-13 | 334.00K shares derived: sum of 2 quarters · filed 2017-11-13 | 285.00K shares 10-Q · filed 2016-11-14 | ||
| 2016-06-30 | 49.00K shares 10-Q · filed 2017-08-14 | ||||
| 2014-03-31 | 825.97M shares 10-Q · filed 2014-05-15 | ||||
| 2013-03-31 | 0.00 shares 10-Q · filed 2013-05-13 | ||||
| 2012-03-31 | 0.00 shares 10-Q · filed 2013-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |